Precigen to Participate in Guggenheim Healthcare Talks Oncology Day
02/04/2021 - 04:05 PM
GERMANTOWN, Md. , Feb. 4, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Precigen, will participate in a virtual fireside chat at the Guggenheim Healthcare Talks Oncology Day on Friday, February 12, 2021 at 11:30 AM ET .
Participants may access the live webcast of the virtual event through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations .
Precigen: Advancing Medicine with Precision™ Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen and LinkedIn .
View original content to download multimedia:http://www.prnewswire.com/news-releases/precigen-to-participate-in-guggenheim-healthcare-talks-oncology-day-301222576.html
SOURCE Precigen, Inc.
PGEN Rankings
#4216 Ranked by Stock Gains
PGEN Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
Country
US
City
Germantown
About PGEN
precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua